Vertex Pharmaceuticals INC
-$3.2B
Net Activity
Institutions Holding
1698
Popularity Rank
#180
Avg Weight
0.24%
Total Value
$104.9B
1698 institutions currently hold VRTX, with 817 net buyers and 707 net sellers this quarter.
Institutional Moves (Q1 2026)
Neutral
Based on recent trading activity
Net Selling Institutions
707
Net Buying Institutions
817
Top 5 by Value
+$55.9B
Total Buy Value
$46.2B
Total Sell Value
817
Net Buyers
707
Net Sellers
VRTX Neutral: Institutional Breadth vs Value, Insider Selling
Signal Basis
Institutional net value fell $3.2B yet 817 buyers vs 707 sellers; insiders sold $2.3M across 4 trades with zero buys.
Confirmation
A continued insider selling streak without institutional buying convergence would tilt bearish; a reversal in value trend with insider buying would turn bullish.
Invalidation Risk
A clear quarter of institutional accumulation (value up, buyer count dominant) coupled with insider buying would negate the neutral call.
AI-generated from public SEC disclosures and limited to historical data. Should not be relied upon as the sole basis for any investment decision.
0
unique buyers
—
buy value
12-Month Buy/Sell Activity
| Action | Insider | Date | Value |
|---|---|---|---|
| Sell | Ourania Tatsis | 2026-07-02 | $787K |
| Sell | Duncan Mckechnie | 2026-07-02 | $800K |
| Sell | Joy Liu | 2026-07-01 | $416K |
| Sell | Bozic Carmen | 2026-06-26 | $288K |
| Sell | Bozic Carmen | 2026-03-27 | $1.05M |
| Sell | Bozic Carmen | 2026-03-13 | $1.12M |
| Sell | Duncan Mckechnie | 2026-03-11 | $1.31M |
| Sell | Duncan Mckechnie | 2026-03-04 | $1.16M |
7
Filings (90d)
$5.38M
Total Est. Value
11K shares
Planned Shares
| Filer | Filing Date | Est. Value |
|---|---|---|
| Tatsis Ourania | 2026-07-02 | $787K |
| McKechnie Duncan | 2026-07-02 | $800K |
| Liu Joy | 2026-07-01 | $416K |
| Bozic Carmen | 2026-06-26 | $288K |
| Bozic Carmen | 2026-06-18 | $471K |
| Bozic Carmen | 2026-06-15 | $1.83M |
| Bozic Carmen | 2026-06-05 | $785K |
Form 144 is a planned sale notice, not an executed transaction. Form 144 Tracker。
No Schedule 13D/13G filings for this ticker
1
Filings (14d)
Vertex Pharmaceuticals has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, with the deal expected to close in the third quarter of 2026. The acquisition is subject to shareholder approval and regulatory clearances. Crinetics's outstanding stock options and restricted stock units will also be cashed out under the terms.
View Full Filing (SEC EDGAR)Other stocks in the same GICS sector
Institutions Holding
4,603
Total reported value
$438.8B
1535 institutions currently hold both VRTX and this stock
Institutions Holding
4,337
Total reported value
$730.5B
1582 institutions currently hold both VRTX and this stock
Institutions Holding
4,024
Total reported value
$283.9B
1505 institutions currently hold both VRTX and this stock
The most-added stocks by 13F institutions this quarter
Institutions Holding
6,150
Total reported value
$2.1T
3245 13F institutions increased their position this quarter
Institutions Holding
5,957
Total reported value
$1.5T
3028 13F institutions increased their position this quarter
Institutions Holding
5,764
Total reported value
$3.0T
2743 13F institutions increased their position this quarter